Talkspace (TALK) 10-Q 8 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Nov. 04, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	TALKSPACE, INC.
Entity Central Index Key	0001803901
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		159,149,884
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-39314
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-4636604
City Area Code	212
Local Phone Number	284-7206
Document Quarterly Report	true
Document Transition Report	false
Common stock
Document Information [Line Items]
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	TALK
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase common stock
Trading Symbol	TALKW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 152,639	$ 198,256
Accounts receivable, net of reserves of $3,294 and $4,918 as of September 30, 2022 and December 31, 2021, respectively	8,692	5,512
Other current assets	4,606	9,562
Total current assets	165,937	213,330
Property and equipment, net	845	624
Intangible assets, net	2,714	3,436
Goodwill	6,134	6,134
Other long-term assets	0	82
Total assets	175,630	223,606
CURRENT LIABILITIES:
Accounts payable	10,360	7,429
Deferred revenues	5,458	7,186
Accrued expenses and other current liabilities	13,206	12,562
Total current liabilities	29,024	27,177
Warrant liabilities	3,649	4,070
Other long-term liabilities	288	86
Total liabilities	32,961	31,333
Commitments and contingencies (Note 5)
STOCKHOLDERS' DEFICIT:
Common stock of $0.0001 par value - Authorized: 1,000,000,000 shares at September 30, 2022 and December 31, 2021; Issued and outstanding: 158,991,019 and 152,862,447 shares at September 30, 2022 and December 31, 2021, respectively	15	15
Additional paid-in capital	375,549	363,788
Accumulated deficit	(232,895)	(171,530)
Total stockholders' equity	142,669	192,273
Total liabilities and stockholders' equity	$ 175,630	$ 223,606

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Allowance, Accounts Receivable	$ 3,294	$ 4,918
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	158,991,019	152,862,447
Common stock, shares outstanding	158,991,019	152,862,447

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues	$ 29,332	$ 26,359	$ 89,326	$ 84,499
Cost of revenues	14,737	12,187	45,163	33,698
Gross profit	14,595	14,172	44,163	50,801
Operating expenses:
Research and development, net	6,182	4,278	16,793	12,023
Clinical operations	2,222	1,896	6,314	5,886
Sales and marketing	18,375	26,431	58,714	75,125
General and administrative	7,667	6,794	24,469	23,112
Total operating expenses	34,446	39,399	106,290	116,146
Operating (loss)	(19,851)	(25,227)	(62,127)	(65,345)
Financial income, net	1,885	26,743	889	23,700
(Loss) income before taxes on income	(17,966)	1,516	(61,238)	(41,645)
Taxes on income	17	11	127	29
Net (loss) income	$ (17,983)	$ 1,505	$ (61,365)	$ (41,674)
Net (loss) income per share:
Basic	$ (0.11)	$ 0.01	$ (0.39)	$ (0.64)
Diluted	$ (0.11)	$ 0.01	$ (0.39)	$ (0.64)
Weighted average number of common shares:
Basic	158,330,684	152,267,870	156,056,900	64,638,182
Diluted	158,330,684	165,179,012	156,056,900	64,638,182

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance, value at Dec. 31, 2020		$ 111,282
Beginning balance, shares at Dec. 31, 2020		94,582,550
Beginning balance, value at Dec. 31, 2020	$ (98,898)		$ 1	$ 9,889	$ (108,788)
Beginning balance, shares at Dec. 31, 2020			13,413,431
Exercise of stock options	797			797
Exercise of stock options, share			684,923
Stock-based compensation	1,513			1,513
Issuance of warrants	125			125
Net loss	(12,738)				(12,738)
Ending balance, value at Mar. 31, 2021		$ 111,282
Ending balance, shares at Mar. 31, 2021		94,582,550
Ending balance, value at Mar. 31, 2021	(109,201)		$ 1	12,324	(121,526)
Ending balance, shares at Mar. 31, 2021			14,098,354
Beginning balance, value at Dec. 31, 2020		$ 111,282
Beginning balance, shares at Dec. 31, 2020		94,582,550
Beginning balance, value at Dec. 31, 2020	(98,898)		$ 1	9,889	(108,788)
Beginning balance, shares at Dec. 31, 2020			13,413,431
Net loss	(41,674)
Ending balance, value at Sep. 30, 2021	206,883		$ 15	357,330	(150,462)
Ending balance, shares at Sep. 30, 2021			152,293,298
Beginning balance, value at Mar. 31, 2021		$ 111,282
Beginning balance, shares at Mar. 31, 2021		94,582,550
Beginning balance, value at Mar. 31, 2021	(109,201)		$ 1	12,324	(121,526)
Beginning balance, shares at Mar. 31, 2021			14,098,354
Common stock issued related to exercise of warrants, value	609			609
Common stock issued related to exercise of warrants, shares			98,871
Acquisition of warrants, Amount	27,945			27,945
Exercise of stock options	1,128			1,128
Exercise of stock options, share			2,617,908
Stock-based compensation	15,196			15,196
Preferred stock conversion, Share		(94,582,550)	94,582,550
Preferred stock conversion, Value	111,282	$ (111,282)	$ 10	111,272
Issuance of common stock in connection with Business Combination and PIPE offering, net of issuance costs, Amount	185,743		$ 4	185,739
Issuance of common stock in connection with Business Combination and PIPE offering, net of issuance costs, Shares			40,858,053
Net loss	(30,441)				(30,441)
Ending balance, shares at Jun. 30, 2021		0
Ending balance, value at Jun. 30, 2021	202,261		$ 15	354,213	(151,967)
Ending balance, shares at Jun. 30, 2021			152,255,736
Exercise of stock options	45			45
Exercise of stock options, share			37,562
Stock-based compensation	3,875			3,875
Issuance of common stock in connection with Business Combination and PIPE offering, net of issuance costs, Amount	(803)			(803)
Net loss	1,505				1,505
Ending balance, value at Sep. 30, 2021	206,883		$ 15	357,330	(150,462)
Ending balance, shares at Sep. 30, 2021			152,293,298
Beginning balance, value at Dec. 31, 2021		$ 0
Beginning balance, shares at Dec. 31, 2021		0
Beginning balance, value at Dec. 31, 2021	$ 192,273		$ 15	363,788	(171,530)
Beginning balance, shares at Dec. 31, 2021	152,862,447		152,862,447
Exercise of stock options	$ 2,063			2,063
Exercise of stock options, share			2,164,870
Restricted Stock Units Vested	(67)			(67)
Restricted Stock Units Vested Shares			77,338
Stock-based compensation	2,368			2,368
Net loss	(20,360)				(20,360)
Ending balance, value at Mar. 31, 2022		$ 0
Ending balance, shares at Mar. 31, 2022		0
Ending balance, value at Mar. 31, 2022	176,277		$ 15	368,152	(191,890)
Ending balance, shares at Mar. 31, 2022			155,104,655
Beginning balance, value at Dec. 31, 2021		$ 0
Beginning balance, shares at Dec. 31, 2021		0
Beginning balance, value at Dec. 31, 2021	$ 192,273		$ 15	363,788	(171,530)
Beginning balance, shares at Dec. 31, 2021	152,862,447		152,862,447
Net loss	$ (61,365)
Ending balance, value at Sep. 30, 2022	$ 142,669		$ 15	375,549	(232,895)
Ending balance, shares at Sep. 30, 2022	158,991,019		158,991,019
Beginning balance, value at Mar. 31, 2022		$ 0
Beginning balance, shares at Mar. 31, 2022		0
Beginning balance, value at Mar. 31, 2022	$ 176,277		$ 15	368,152	(191,890)
Beginning balance, shares at Mar. 31, 2022			155,104,655
Exercise of stock options	286			286
Exercise of stock options, share			1,092,515
Restricted Stock Units Vested	(126)			(126)
Restricted Stock Units Vested Shares			1,175,446
Stock-based compensation	3,839			3,839
Net loss	(23,022)				(23,022)
Ending balance, value at Jun. 30, 2022		$ 0
Ending balance, shares at Jun. 30, 2022		0
Ending balance, value at Jun. 30, 2022	157,254		$ 15	372,151	(214,912)
Ending balance, shares at Jun. 30, 2022			157,372,616
Exercise of stock options	347			347
Exercise of stock options, share			893,194
Restricted Stock Units Vested	(128)			(128)
Restricted Stock Units Vested Shares			725,209
Stock-based compensation	3,179			3,179
Net loss	(17,983)				(17,983)
Ending balance, value at Sep. 30, 2022	$ 142,669		$ 15	$ 375,549	$ (232,895)
Ending balance, shares at Sep. 30, 2022	158,991,019		158,991,019

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (61,365)	$ (41,674)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,006	1,458
Amortization of debt issuance cost		175
Stock-based compensation	9,386	20,584
Warrant change in fair value	(421)	(23,842)
(Increase) decrease in accounts receivable, net	(3,180)	596
Decrease (increase) in other current assets	4,848	(8,515)
Increase in accounts payable	2,931	7,113
(Decrease) increase in deferred revenues	(1,728)	3,130
Increase (decrease) in accrued expenses and other current liabilities	1,465	(134)
Increase in other long-term liabilities	202	0
Net cash used in operating activities	(46,856)	(41,109)
Cash flows from investing activities:
Purchase of property and equipment	(254)	(622)
Net cash used in investing activities	(254)	(622)
Cash flows from financing activities:
(Payments) proceeds from reverse capitalization, net of transaction costs	(645)	249,428
Proceeds from borrowings	0	6,000
Repayment of borrowings	0	(6,000)
Payment of debt issuance costs	0	(50)
Proceeds from exercise of stock options	2,696	1,970
Payments for employee taxes withheld related to vested stock-based awards	(558)	0
Net cash provided by financing activities	1,493	251,348
Net (decrease) increase in cash and cash equivalents	(45,617)	209,617
Cash and cash equivalents at the beginning of the period	198,256	13,248
Cash and cash equivalents at the end of the period	152,639	222,865
Supplemental cash flow data:
Cash paid during the period for interest	46	115
Cash paid during the period for income taxes	122	0
Non-Cash financing activities:
Conversion of preferred stock to common stock	$ 0	$ 111,282

Description of Organization and

Description of Organization and Business Operations	9 Months Ended
	Sep. 30, 2022
Description Of Organisation And Business Operation [Abstract]
Description of organization and business operations	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Talkspace, Inc. (together with its consolidated subsidiaries, the “Company” or “Talkspace”) is a leading behavioral healthcare company enabled by a purpose-built technology platform. Talkspace provides individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Talkspace was originally incorporated as Hudson Executive Investment Corp. (“HEC”). In connection with the Business Combination completed in June 2021, HEC changed its name to “Talkspace, Inc.” Operating Segments The Company operates its business as a single segment and as one reporting unit, which is how the Company's chief operating decision maker (who is the interim chief executive officer) reviews financial performance and allocates resources.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2. SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2021, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company’s policy is to consolidate all subsidiaries in which it has a controlling financial interest, as well as any Variable Interest Entities (“VIEs”) where the Company is deemed to be the primary beneficiary when it has the power to make the decisions that most significantly affect the economic performance of the VIE and has the obligation to absorb significant losses or the right to receive benefits that could potentially be significant to the VIE. In the second quarter of 2022, the Company completed the transition of its structure with respect to its relationships with healthcare providers and certain affiliated professional association and professional corporations in which it holds a variable interest. These affiliated professional association and professional corporations are now considered VIEs since they do not have sufficient equity to finance their activities without additional subordinated financial support from the Company. The Company determined that it is the primary beneficiary of the VIEs and as a result consolidated them in its financial statements. All intercompany transactions and balances have been eliminated. See Note 11, “Variable Interest Entities,” for further details. Use of estimates The preparation of consolidated financial statements, in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Recently Issued and Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The amendments in this ASU became effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this guidance on January 1, 2022 and the adoption did not have a significant impact on its condensed consolidated financial statements or related disclosures. In May 2021, the FASB issued ASU 2021-04—Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in accounting for modifications or exchanges of freestanding equity-written call options that remain equity classified after modifications or exchanges based on the substance of the transactions. The amendments in this ASU became effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures. In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer's Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments in this ASU became effective for public entities excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	NOTE 3. REVENUE RECOGNITION The Company operates a virtual behavioral healthcare business that connects individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Individuals access the Company’s services through the Company’s website or mobile app. The Company provides its services through two channels, the business-to-business (“B2B”) channel, comprised of large health plans and employee assistance programs such as Aetna, Cigna, Premera and Optum and large enterprise clients such as Google and Expedia, who offer their employees and insured members access to the Company's platform while their employer is under an active contract with Talkspace, or at in-network reimbursement rates, where applicable, and the business-to-consumer (“B2C”) channel, comprised of individual consumers who subscribe directly to the Company's platform. B2B Revenue The Company contracts with health plans and other enterprises to provide its services to individuals who are qualified to receive access to the Company’s services through the Company’s commercial arrangements. The Company generates revenues from payments from members and claims paid by their respective insurance companies and annually contracted platform access fees paid by the Company's enterprise clients for the delivery of therapy services to their members or employees. The Company recognizes revenues from services provided to insured members at a point in time, as virtual therapy session is rendered. The Company recognizes contracted revenue from enterprise clients from the commencement of their contracted term through the annual period based primarily on a per-member-per month model. Revenue is recognized in an amount that reflects the consideration that is expected in exchange for the service provided. Contracts with enterprise clients are for one or more years with the ability to provide 60 days advance notice prior to termination at each year mark during the term. After the first year of service, certain clients have the right to terminate their contract with a 60 or 90 days notice. B2C Revenue The Company generates revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to the Company's therapy platform as well as supplementary a la carte offerings. The Company provides these services directly to individuals through a subscription plan. The Company recognizes member subscription revenues ratably over the subscription period, beginning when therapy services commence. The Company recognizes revenues from supplementary a la carte offerings at a point in time, as virtual therapy session is rendered. Members may cancel at any time and will receive a pro-rata refund for the subscription price. The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended September 30,  Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Revenues from sales to unaffiliated customers: B2B revenue $ 16,793 $ 7,728  $ 45,129 $ 26,213 B2C revenue 12,539 18,631  44,197 58,286 Total $ 29,332 $ 26,359  $ 89,326 $ 84,499 Accounts Receivable and Revenue Reserves Revenue reserves are deducted from accounts receivable to present the net amount expected to be collected. As of September 30, 2022, revenue reserves mainly relate to allowances for accounts receivable balances from health insurance and EAP organizations. During the nine months ended September 30, 2022 and 2021 , the Company recorded an increase in revenue reserves of $ 1.9 million and $ 3.6 million, respectively ($ 0.9 million and $ 3.4 million during the three months ended September 30, 2022 and 2021, respectively). During the nine months ended September 30, 2022 , the Company wrote-off $ 3.5 million of its aged receivables that were previously fully reserved. There were no write-offs of aged balances during the nine months ended September 30, 2021. As of September 30, 2022 , the balance of receivables related to health insurance and EAP organizations was $ 5.6 million and the revenue reserves against these receivables was $ 3.3 million, of which $ 0.3 million relates to aged balances for periods prior to 2022. Deferred Revenue The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. As of September 30, 2022, deferred revenue related mainly to the Company’s B2C subscription business. The Company recognizes deferred revenues as revenues in the statement of operations once performance obligations have been performed and satisfied. The Company expects to satisfy the majority of its performance obligations associated with deferred revenue within one year or less. Contract Costs The Company elected to use the practical expedient to recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 4. FAIR VALUE MEASUREMENT The carrying value of the Company’s cash equivalents, accounts receivable, other current assets, accounts payable, and accrued liabilities approximate fair value because of the relatively short-term nature of the underlying assets. The Company’s Private Placement Warrants are carried at fair value with changes in fair value recognized in earnings each period. The Private Placement Warrants assumed in connection with the consummation of the Business Combination and the closing of the Forward Purchase Agreement with the HEC Fund are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities were measured at fair value at inception and thereafter on a recurring, quarterly basis, with changes in fair value presented within financial expense, net, in the condensed consolidated statement of operations. The Private Placement Warrants were valued using the Black-Scholes-Merton Model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the Company’s common stock. For the three and nine months ended September 30, 2022 , the Company had gains related to the remeasurement of the Private Placement Warrants of $ 1.6 million and $ 0.4 million, respectively. For the three and nine months ended September 30, 2021 , the Company had gains related to the remeasurement of the Private Placement Warrants of $ 26.9 million and $ 28.3 million, respectively. The following table presents the changes in the fair value of warrant liabilities during the three and nine months ended September 30, 2022: Level 3 Liabilities For the Three Months Ended September 30, 2022 (in thousands) Beginning Balance Change in Fair Value Ending Balance Private Placement Warrants $ 5,287 $ ( 1,638 ) $ 3,649 Level 3 Liabilities For the Nine Months Ended September 30, 2022 (in thousands) Beginning Balance Change in Fair Value Ending Balance Private Placement Warrants $ 4,070 $ ( 421 ) $ 3,649

Commitments and Contingent Liab

Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 5. COMMITMENTS AND CONTINGENT LIABILITIES Lease commitments Since terminating its prior office lease agreement in August 2020, the Company had a month to month operating lease for office space in New York City. In the fourth quarter of 2022, the Company entered into a long-term sublease agreement for new office space in New York City. This new sublease will not have a material impact on the Company's financial results. As of September 30, 2022, the Company's workforce is fully remote. The Company has limited operations outside the United States. The Company has one foreign subsidiary located in Israel which leases its operating facilities under a month-to-month operating lease agreement. The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize right-of-use (“ROU”) assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for all of the Company’s leases. Rent expenses under the Company’s short-term operating leases for the three and nine months ended September 30, 2022 was $ 48,000 and $ 158,000 respectively. Litigation The Company is and may in the future be involved in various legal proceedings arising from the normal course of business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that any such litigation or claims are unlikely to have any material adverse impact on the Company’s consolidated results of operations, cash flows or financial position. Regardless of the outcome, however, litigation can have an adverse impact on the Company because of the costs to defend lawsuits, diversion of management resources and other factors. In January 2022, the Company and certain of its current and former officers and directors were named as defendants in securities class action complaints filed in the United States District Court for the Southern District of New York (the “Securities Actions”) under the case headings: (1) Baron v. Talkspace et al ., No. 22-cv-00163 (S.D.N.Y.) and (2) Valdez v. Talkspace et al ., No. 22-cv-00840 (S.D.N.Y.). The Securities Actions asserted violations of sections 10(b), 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rules 10b-5 and 14a-9 promulgated thereunder. The Securities Actions generally relate to public disclosures and statements by the Company in connection with its merger with HEC. The core allegations are that in connection with the merger, defendants made material misstatements and omissions regarding Talkspace’s business, financial condition, and growth prospects. The complaints seek, among other things, damages on behalf of all members of the proposed class. In June 2022, the Securities Actions were consolidated under the caption In re Talkspace, Inc. Securities Litigation (the “Consolidated Securities Action”). On August 1, 2022, plaintiffs in the Consolidated Securities Action filed a consolidated class action complaint, which asserted the same violations of sections 10(b), 14(a), and 20(a) of the Securities Exchange Act of 1934 and SEC Rules 10b-5 and 14a-9 as described above. Defendants have moved to dismiss the consolidated class action complaint. In June and July 2022, individuals filed stockholder derivative lawsuits purportedly on behalf of Talkspace, in the United States District Court for the Southern District of New York under the case captions: (1) Odsvall v. Oren Frank et al ., No. 22-cv-05016 (S.D.N.Y.) and (2) Nayman v. Berg, et al ., No. 22-cv-06258 (S.D.N.Y.) (the “Derivative Actions”). The Derivative Actions name certain of the Company’s current and former officers and directors as defendants and the Company as a nominal defendant. The Derivative Actions assert claims for violations of federal securities laws, breach of fiduciary duty, and aiding and abetting breach of fiduciary duty relating to the merger with HEC, among other things, based on many of the same facts at issue in the Consolidated Securities Action. The complaint in Odsvall v. Oren Frank et al. additionally alleges that the individual defendants breached their fiduciary obligations to Talkspace by permitting misleading statements to be published in a proxy statement, press releases, and other public filings and announced on a quarterly earnings call. The complaints seek, among other things, damages on behalf of the Company, restitution and injunctive relief. In September 2022, the Derivative Actions were consolidated under the caption In re Talkspace Stockholder Derivative Litigation (the “Consolidated Derivative Action”). All proceedings and deadlines in the Consolidated Derivative Action have stayed pending a final decision on the defendants’ motion to dismiss the consolidated class action complaint in the Consolidated Securities Action. The Company is not able to predict the outcome of these lawsuits, nor can it predict the amount of time and expense that will be required to resolve the lawsuits. The Company believes that the lawsuits are without merit and intends to vigorously defend against them. The Company incurred an increase in legal fees associated with these lawsuits in the third quarter of 2022. In addition to the foregoing, from time-to-time, the Company is party to various legal proceedings, claims and litigation that arise in the normal course of business. In the opinion of management, the ultimate outcome of these matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated. Warranties and Indemnification The Company’s arrangements generally include certain provisions for indemnifying clients against liabilities if there is a breach of a client’s data or if the Company’s service infringes a third party’s intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by the Company, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Capital Stock	NOTE 6. CAPITAL STOCK The Company’s authorized capital stock consists of (a) 1,000,000,000 shares of common stock, par value $ 0.0001 per share; a nd (b) 100,000,000 shares of preferred stock, par value $ 0.0001 per share. As of September 30, 2022 , there were 158,991,019 shares of common stock issued and outstanding ( 152,862,447 as of December 31, 2021). As of September 30, 2022 and December 31, 2021 there were 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase t he Company’s common stock at an exercise price of $ 11.50 per share . As of September 30, 2022 and December 31, 2021 , no shares of preferred stock were issued or outstanding.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	NOTE 7. SHARE-BASED COMPENSATION The Company adopted the 2014 Stock Incentive Plan (the “2014 Plan”) pursuant to which incentive and nonqualified stock options and stock purchase rights to purchase the Company’s common stock may be granted to officers, employees, directors, consultants and service providers. In connection with the closing of the Business Combination, the Company adopted the 2021 Incentive Award Plan (the “2021 Plan”) under which the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent. In connection with the effectiveness of the 2021 Plan, no further awards will be granted under the 2014 Plan. Employees, consultants and directors of the Company, and employees and consultants of its subsidiaries, are eligible to receive awards under the 2021 Plan. In connection with the closing of the Business Combination, the Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”) under which employees of Talkspace and its participating subsidiaries are provided with the opportunity to purchase Talkspace common stock at a discount through accumulated payroll deductions during successive offering periods. As of September 30, 2022, no employee stock purchases have been made under the 2021 ESPP. All stock-based awards are measured based on the grant date fair value and are generally recognized on a straight-line basis in the Company’s condensed consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period). The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Research and development, net $ 630 $ 483 $ 1,838 $ 2,000 Clinical Operations 113 288 314 575 Sales and Marketing 793 1,081 2,386 5,100 General and administrative 1,643 2,023 4,848 12,909 Total stock-based compensation expense $ 3,179 $ 3,875 $ 9,386 $ 20,584

Net (Loss) Income Per Share

Net (Loss) Income Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	NOTE 8. NET (LOSS) INCOME PER SHARE The following table sets forth the computation of basic and diluted net (loss) income per share attributable to common stockholders for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share data) 2022 2021 2022 2021 Net (loss) income $ ( 17,983 ) $ 1,505 $ ( 61,365 ) $ ( 41,674 ) Weighted average number of common shares: Basic 158,330,684 152,267,870 156,056,900 64,638,182 Diluted 158,330,684 165,179,012 156,056,900 64,638,182 Net (loss) income per share: Basic $ ( 0.11 ) $ 0.01 $ ( 0.39 ) $ ( 0.64 ) Diluted $ ( 0.11 ) $ 0.01 $ ( 0.39 ) $ ( 0.64 ) For the three and nine months ended September 30, 2022 , the following were excluded from the calculation of diluted net loss per share since each would have had an anti-dilutive effect: 17,746,401 stock options, 6,670,934 restricte d stock units, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock. For the three months ended September 30, 2021, the following were excluded from the calculation of diluted income per share since each would have had an anti-dilutive effect: 7,396,187 stock options, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock. For the nine months ended September 30, 2021, the following were excluded from the calculation of diluted loss per share since each would have had an anti-dilutive effect: 24,182,910 stock options, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock.

Taxes on Income

Taxes on Income	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Taxes on Income	NOTE 9. TAXES ON INCOME As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its deferred tax assets for assets that are not expected to be realized. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other Current Liabilities Abstract
Accrued Expenses and Other Current Liabilities	NOTE 10. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities are comprised of the following: (in thousands) September 30, 2022 December 31, 2021 Employee compensation $ 6,528 $ 5,988 User acquisition 2,804 2,680 Professional fees 891 1,303 Other 2,983 2,591 Accrued expenses and other current liabilities $ 13,206 $ 12,562

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
VARIABLE INTEREST ENTITIES ("VIEs")	NOTE 11. VARIABLE INTEREST ENTITIES ("VIEs" ) In the second quarter of 2022, the Company completed its transition with respect to its relationships with healthcare providers under Talkspace Provider Network, PA (“TPN”), a Texas professional association entity. The Company's wholly owned subsidiary, Talkspace LLC, is party to various Management Services Agreements (“MSAs”) between it and TPN as well as other affiliated professional entities ("PC entities") as part of this transition. TPN and the PC entities, where applicable, contract with physicians, therapists, and other licensed professionals for clinical and professional services provided to the Company’s members. The Company believes the transition to a structure where it operates under various MSAs with professional associations and professional corporations authorized by state law to contract with affiliated professionals to delivery teletherapy services to its members, will help ensure the Company is able to comply with all applicable regulatory requirements, including the corporate practice of medicine and fee-splitting laws, that are necessarily implicated by engaging in telehealth care that can only be delivered by physicians. The Company is continuing to transition its current agreements with its clients, members and other business partners to TPN or the PC entities, where applicable. Pursuant to the MSAs, Talkspace LLC is the manager entity (the “Manager”) and provides management and administrative resources and services essential to the operations of TPN and the PC entities and receives a management fee for these services and reimbursement of expenses incurred. TPN and the PC entities in turn have the obligation under the MSAs to engage all licensed physicians and other health professionals to provide behavioral healthcare services to the Company's members. As of September 30, 2022, the PC entities are not active and no activity has been recorded under these entities. The Company holds a variable interest in TPN. TPN is considered a variable interest entity (“VIE”) under Accounting Standard Codification 810, Consolidation, since it does not have sufficient equity to finance its activities without additional subordinated financial support. An entity having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control the activities of TPN that most significantly impact TPN's economic performance and the obligation to absorb all losses or the right to receive the benefits from TPN, and as a result TPN is consolidated in the Company’s financial statements. In addition, no non-controlling interest is recorded in respect of TPN as it has a single individual shareholder who has no right to dividends or residual interest. The following table details the assets and liabilities of the Company's consolidated VIE: (in thousands) September 30, 2022 ASSETS Cash and cash equivalents $ 895 Other assets 1,624 Total Assets $ 2,519 LIABILITIES Accrued expenses and other current liabilities 3,486 Total Liabilities $ 3,486

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2021, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company’s policy is to consolidate all subsidiaries in which it has a controlling financial interest, as well as any Variable Interest Entities (“VIEs”) where the Company is deemed to be the primary beneficiary when it has the power to make the decisions that most significantly affect the economic performance of the VIE and has the obligation to absorb significant losses or the right to receive benefits that could potentially be significant to the VIE. In the second quarter of 2022, the Company completed the transition of its structure with respect to its relationships with healthcare providers and certain affiliated professional association and professional corporations in which it holds a variable interest. These affiliated professional association and professional corporations are now considered VIEs since they do not have sufficient equity to finance their activities without additional subordinated financial support from the Company. The Company determined that it is the primary beneficiary of the VIEs and as a result consolidated them in its financial statements. All intercompany transactions and balances have been eliminated. See Note 11, “Variable Interest Entities,” for further details.
Use of estimates	Use of estimates The preparation of consolidated financial statements, in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The amendments in this ASU became effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this guidance on January 1, 2022 and the adoption did not have a significant impact on its condensed consolidated financial statements or related disclosures. In May 2021, the FASB issued ASU 2021-04—Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in accounting for modifications or exchanges of freestanding equity-written call options that remain equity classified after modifications or exchanges based on the substance of the transactions. The amendments in this ASU became effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures. In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer's Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments in this ASU became effective for public entities excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue by Revenue Source	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended September 30,  Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Revenues from sales to unaffiliated customers: B2B revenue $ 16,793 $ 7,728  $ 45,129 $ 26,213 B2C revenue 12,539 18,631  44,197 58,286 Total $ 29,332 $ 26,359  $ 89,326 $ 84,499

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of warrants	The following table presents the changes in the fair value of warrant liabilities during the three and nine months ended September 30, 2022: Level 3 Liabilities For the Three Months Ended September 30, 2022 (in thousands) Beginning Balance Change in Fair Value Ending Balance Private Placement Warrants $ 5,287 $ ( 1,638 ) $ 3,649 Level 3 Liabilities For the Nine Months Ended September 30, 2022 (in thousands) Beginning Balance Change in Fair Value Ending Balance Private Placement Warrants $ 4,070 $ ( 421 ) $ 3,649

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense	The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Research and development, net $ 630 $ 483 $ 1,838 $ 2,000 Clinical Operations 113 288 314 575 Sales and Marketing 793 1,081 2,386 5,100 General and administrative 1,643 2,023 4,848 12,909 Total stock-based compensation expense $ 3,179 $ 3,875 $ 9,386 $ 20,584

Net (Loss) Income Per Share (Ta

Net (Loss) Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net (loss) income per share attributable to common stockholders for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share data) 2022 2021 2022 2021 Net (loss) income $ ( 17,983 ) $ 1,505 $ ( 61,365 ) $ ( 41,674 ) Weighted average number of common shares: Basic 158,330,684 152,267,870 156,056,900 64,638,182 Diluted 158,330,684 165,179,012 156,056,900 64,638,182 Net (loss) income per share: Basic $ ( 0.11 ) $ 0.01 $ ( 0.39 ) $ ( 0.64 ) Diluted $ ( 0.11 ) $ 0.01 $ ( 0.39 ) $ ( 0.64 )

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other Current Liabilities Abstract
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities are comprised of the following: (in thousands) September 30, 2022 December 31, 2021 Employee compensation $ 6,528 $ 5,988 User acquisition 2,804 2,680 Professional fees 891 1,303 Other 2,983 2,591 Accrued expenses and other current liabilities $ 13,206 $ 12,562

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Assets and liabilities of the Company's consolidated VIE	The following table details the assets and liabilities of the Company's consolidated VIE: (in thousands) September 30, 2022 ASSETS Cash and cash equivalents $ 895 Other assets 1,624 Total Assets $ 2,519 LIABILITIES Accrued expenses and other current liabilities 3,486 Total Liabilities $ 3,486

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregation of Revenue by Revenue Source (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues fom sales to unaffiliated customers:
Total Revenue	$ 29,332	$ 26,359	$ 89,326	$ 84,499
B2B Revenue
Revenues fom sales to unaffiliated customers:
Total Revenue	16,793	7,728	45,129	26,213
B2C Revenue
Revenues fom sales to unaffiliated customers:
Total Revenue	$ 12,539	$ 18,631	$ 44,197	$ 58,286

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Increase In Revenue Reserve	$ 900	$ 3,400	$ 1,900	$ 3,600
Accounts receivable, net	8,692		8,692		$ 5,512
Aged receivables wrote-off			3,500	$ 0
Revenue Reserves	3,300		3,300
Aged Balances	300		300
Health Plans and EAP Customers
Disaggregation of Revenue [Line Items]
Accounts receivable, net	$ 5,600		$ 5,600

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Private Placement Warrants
Gain on remeasurement of warrant	$ 1.6	$ 26.9	$ 0.4	$ 28.3

Fair Value Measurements - Summa

Fair Value Measurements - Summary of warrants (Detail) - Private Placement Warrants - Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Class of Warrant or Right [Line Items]
Fair value as of beginning	$ 5,287	$ 4,070
Change in value	(1,638)	(421)
Fair value as of ending	$ 3,649	$ 3,649

Commitments and Contingent Li_2

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Rental Expense	$ 48,000	$ 158,000

Capital Stock - Additional Info

Capital Stock - Additional Information (Details) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000
Preferred stock, par value	$ 0.0001
Common Stock Shares Issued	158,991,019	152,862,447
Common stock, shares outstanding	158,991,019	152,862,447
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50	$ 11.50
Preferred Stock Shares Issued	0	0
Preferred stock, shares outstanding	0	0
Private Placement Warrants
Class of Stock [Line Items]
Warrants and Rights Outstanding	12,780,000	12,780,000
Public Warrants
Class of Stock [Line Items]
Warrants and Rights Outstanding	21,350,000	21,350,000

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 3,179			$ 3,875			$ 9,386	$ 20,584
Common stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise of stock options, share	893,194	1,092,515	2,164,870	37,562	2,617,908	684,923

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	$ 3,179	$ 3,875	$ 9,386	$ 20,584
Research and Development, net
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	630	483	1,838	2,000
Clinical Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	113	288	314	575
Sales and Marketing
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	793	1,081	2,386	5,100
General and Administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	$ 1,643	$ 2,023	$ 4,848	$ 12,909

Net (Loss) Income Per Share - S

Net (Loss) Income Per Share - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net (loss) income	$ (17,983)	$ (23,022)	$ (20,360)	$ 1,505	$ (30,441)	$ (12,738)	$ (61,365)	$ (41,674)
Denominator:
Weighted average number of common shares: Basic	158,330,684			152,267,870			156,056,900	64,638,182
Weighted average number of common shares: Diluted	158,330,684			165,179,012			156,056,900	64,638,182
Net (loss) income per share: Basic	$ (0.11)			$ 0.01			$ (0.39)	$ (0.64)
Net (loss) income per share: Diluted	$ (0.11)			$ 0.01			$ (0.39)	$ (0.64)

Net (Loss) Income Per Share - A

Net (Loss) Income Per Share - Additional Information (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	6,670,934		6,670,934
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	17,746,401	7,396,187	17,746,401	24,182,910
Private Placement Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	12,780,000	12,780,000	12,780,000	12,780,000
Public Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of diluted loss per share	21,350,000	21,350,000	21,350,000	21,350,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Expense and Other Current Liabilities [Abstract]
Employee compensation	$ 6,528	$ 5,988
User acquisition	2,804	2,680
Professional fees	891	1,303
Other	2,983	2,591
Accrued expenses and other current liabilities	$ 13,206	$ 12,562

Variable Interest Entities -Add

Variable Interest Entities -Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Variable interest in TPN
Variable Interest Entity [Line Items]
Variable Interest Entity, Financial or Other Support, Reasons	The Company holds a variable interest in TPN. TPN is considered a variable interest entity (“VIE”) under Accounting Standard Codification 810, Consolidation, since it does not have sufficient equity to finance its activities without additional subordinated financial support. An entity having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control the activities of TPN that most significantly impact TPN's economic performance and the obligation to absorb all losses or the right to receive the benefits from TPN, and as a result TPN is consolidated in the Company’s financial statements. In addition, no non-controlling interest is recorded in respect of TPN as it has a single individual shareholder who has no right to dividends or residual interest.

Variable Interest Entities - Su

Variable Interest Entities - Summary of assets and liabilities of the Company's consolidated VIE (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 152,639	$ 198,256
Total assets	175,630	223,606
LIABILITIES
Accrued expenses and other current liabilities	13,206	$ 12,562
Variable Interest Entity [Member]
ASSETS
Cash and cash equivalents	895
Other assets	1,624
Total assets	2,519
LIABILITIES
Accrued expenses and other current liabilities	3,486
Total Liabilities	$ 3,486